Loading stock data…
IONS
$74.58+1.04 (+1.41%)
Market ClosedLast close Jun 9
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ionis Pharmaceuticals, Inc. in the Healthcare sector is trading at $74.58. Wall Street consensus targets $100.92 (25 analysts), implying a +35.3% move over the next 12 months. The stock is currently 14% below its 52-week high of $86.74, remaining 0.8% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +35.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$74.58
Potential Downside
0%
Whystock Fair Value$74.58
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus25 analysts
Buy
Mean target$100.92+35.3%
Range$47.00 – $130.00
Fundamentals
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pan...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-66.54%
Volume
Today's trading volume
1.55M
Recent News
Assessing Ionis Pharmaceuticals (IONS) Valuation After New Olezarsen Data Plans And Bullish Pipeline Updates
Why olezarsen data and conference appearances matter for Ionis Pharmaceuticals stock Ionis Pharmaceuticals (IONS) is back in focus after fresh updates on its late stage pipeline, including new Phase 3 data for olezarsen in severe hypertriglyceridemia and upcoming conference presentations, drew renewed attention from investors. The company plans to showcase additional analyses from the CORE and CORE2 studies at several medical meetings, while its marketing application for olezarsen in severe...
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter
This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform.
Why Is Ionis Pharmaceuticals (IONS) Up 3.4% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GSK’s hepatitis B drug touts functional curative potential in double Phase III win
Analysts are heralding bepirovirsen as a potentially strong future growth driver for GSK and its infectious disease portfolio.
Why The Story Around Ionis Pharmaceuticals (IONS) Is Shifting After Fresh Analyst Targets And Guidance
The fair value estimate for Ionis Pharmaceuticals has shifted from US$96.73 to US$100.92, a modest reset that puts fresh numbers around the stock. This move comes during an active period of Street research, with some firms lifting targets and others trimming them, reflecting different views on how to factor pipeline milestones and revenue guidance into valuation work. As you read on, you will see what is driving these updates and how to keep track of the evolving analyst narrative around...